+ All Categories
Home > Documents > BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís...

BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís...

Date post: 29-Jul-2020
Category:
Upload: others
View: 0 times
Download: 0 times
Share this document with a friend
14
Transcript
Page 1: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the
Page 2: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the

BD Horizon Brilliant™ Blue 515 brings

innovation to the blue laser in the form of

a novel format that is resolved in the FITC

channel. Developed using technology

from Sirigen, BD Horizon Brilliant Blue 515

is up to seven times brighter than FITC

and offers significantly better resolution,

with less spillover into the PE channel.

BD Horizon Brilliant Blue conjugated

antibodies give researchers new avenues

to resolve dim cell populations, take

advantage of better panel design, and

have more confidence in their results.

This unique blue laser dye is just another

way BD Biosciences continues to innovate

and deliver improvements to the world

of multicolor flow cytometry so that you

can get more out of your research.

To find out about brighter ways to

use blue and obtain free samples, visit

bdbiosciences.com/go/newblue.

Makes working with FITCseem rather dull.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2014 BD23-16321-00

BD Biosciences2350 Qume DriveSan Jose, CA 95131bdbiosciences.com

BD Horizon Brilliant™ Blue 515A brighter blue laser dye with less spillover and better resolution.

Page 3: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the

Suit(Ab)le AntibodiesWe’re selective. We’re specific. We’re scientists.We create the antibodies that are most relevantfor today’s research needs.

As a thoughtful producer, we take a selective approach to offering the best antibodies for each

target. Our team of R&D scientists combs research and collaborates with leading institutions to

identify only the most relevant antibodies for your research. Our expertise combines the pioneering

work of Chemicon® and Upstate®, but our wisdom doesn’t stop there. We constantly review, assess

and determine which antibodies are the most suitable – those which provide the right level and

type of data. It is our job to understand your needs so we can offer you the best of the best.

Put the most suitable antibodies to work for you.

www.emdmillipore.com/Ab

EMD Millipore is a division ofMerck KGaA, Darmstadt, Germany

EMD Millipore and the M logo are trademarks and

Chemicon and Upstate are registered trademarks of

Merck KGaA, Darmstadt, Germany.

© 2014 EMD Millipore Corporation, Billerica, MA USA.

All rights reserved.

BS-GEN-13-09105 03/2014

Page 4: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the

Always been ready for change?

MAKE GREAT THINGS HAPPENOpportunities for graduates and young professionals: If you

are in the process of laying out your future career, why not start

with us? To position ourselves for the years to come, we focus on

continuous improvements in all our businesses and operations.

For that, we need the best and brightest people Ð fresh talents

willing to help us set the course for Merck KGaA, Darmstadt,

Germany with courage, creativity and competence. And ready

to seize an excellent opportunity to advance your own career.

We are ready for change Ð are you?

Merck KGaA, Darmstadt, Germany Ð with more than 300 years of

progress and about 38,000 employees in over 60 countries, we are

leading in chemicals and pharma.

Our subsidiaries in Canada and the United States operate under the

umbrella brand EMD. With passion, dedication and innovative ideas,

we pursue one global goal: to improve peopleÕs quality of life.

Like to join in? Welcome to the team!

come2emd.com

Page 5: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the

Reichert SPR advantage.Support with results.Research is time consuming so support for

your experiment shouldn’t be. Our team will

discuss your SPR applications, arrange for

demonstrations, and install a system in your

research lab. For support with results,

contact Reichert.

For a side-by-side comparisonof Reichert SPR and the competition go to:

ReichertSPR.com/advantage

When you are looking for a system to perform

label-free protein interaction analysis, the

Reichert SR7500DC Surface Plasmon Resonance

(SPR) system is the ideal choice. It’s a fraction

of the price of the leading competitor, with the

same powerful performance. When valuable

research dollars are being watched carefully, the

smart purchase is Reichert.

Reichert surface plasmon resonance systems are the right choice for your lab

Page 6: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the
Page 7: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the

beon the edgeofbiomedical diagnostics

Announcing the international Master of Science in Biomedical Diagnostics program available Fall 2014. This uniqueprogram is based on Dublin City University’s (DCU) award-winning Master of Science in Biomedical Diagnostics.It was developed by Arizona State University, DCU and Ventana Medical Systems, combining the strengths ofthese world-renowned academic institutions and industry leader. The program utilizes new technology-enabledcollaborations to explore the science, business, technology and application of diagnostics. It blends face-to-faceand online courses to position graduates on the cutting-edge of this innovative field.

For more information and how to apply, visit dcu.asu.edu

International School ofBiomedicalDiagnostics

In This Issue

Upcoming Features

Digital Lab ManagementóJuly 25

MetabolomicsóSeptember 19

GenomicsóOctober 3

Big BiologicalImpacts fromBig Data

LIFE SCIENCE TECHNOLOGIESBIOTECH AND PHARMA

Produced by the Science/AAAS Custom Publishing Office

In This Issue

Upcoming Features

Postdocs: Broadening Your Skills óAugust 22

Faculty: Professionalism 1óSeptember 12

Faculty: Professionalism 2óOctober 3

Produced by the Science/AAAS Custom Publishing Office

An Explosion ofBioinformatics

Big data is everywhere, and its in�uence and practical

omnipresence across multiple industries will just continue

to grow. For life scientists with expertise and an interest in

bioinformatics, computer science, statistics, and related

skill sets, the job outlook couldnít be rosier. Big pharma,

biotech, and software companies are clamoring to hire

professionals with experience in bioinformatics and the

identi�cation, compilation, analysis, and visualization of

huge amounts of biological and health care information.

With the rapid development of new tools to make sense of

life science research and outcomes, spurred by innovative

research in bioinformatics itself,

scientists who are entranced by

data can pursue more career op-

tions than ever before. See the

full story on page 1303.

FOCUS ON CAREERSBIG DATA

In the life sciences, data can

come in many forms, including

information about genomic se-

quences, molecular pathways,

and different populations of

people. Those data create a

potential bonanza, if scientists can overcome one stum-

bling block: how to handle the complexity of information.

Tools and techniques for analyzing big data promise to

mold massive mounds of information into a better under-

standing of the basic biological mechanisms and how the

results can be applied in, for example, health care. See

the full story on page 1298.

Page 8: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the

The meeting theme reflects on the information transformation

happening in science and technology brought about by

recent advances in organizing, visualizing, and analyzing data.

Save the Date: 12–16 February 2015

The AAAS Annual Meeting is interdisciplinary and inclusive.

Each year, thousands of leading scientists, engineers, educators,

policymakers, and journalists from around the world gather to

discuss recent developments in science and technology.

Registration opens in early August.

www.aaas.org/meetings

I N N O V A T I O N S , I N F O R M A T I O N , A N D I MAG I N G

Page 9: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the

1298 sciencemag.org/products SCIENCE

LIFE SCIENCE TECHNOLOGIES

BIG DATA

Produced by the Science/AAAS Custom Publishing Office

ìBig dataî is one of todayís hottest concepts, but

it can be misleading. The name itself suggests

mountains of data, but thatís just the start. Overall,

big data consists of three vís: volume of data, velocity of pro-

cessing the data, and variability of data sources. These are the

key features of information that require big-data tools.

Although biologists have spent decades struggling to collect

enough data, says Keith Crandall, director of the Computational

Biology Institute at George Washington University in Ashburn,

Virginia, ìthe new bottlenecks in biology are big-data issues.î

()*+�*��+�����*��*���)*��*�+*��*� )*���+�*������*

sequence, announced in April 2002, utilized the expertise, in-

frastructure, and people from 20 institutions and took 13 years

of work and about $3 billion to determine the order of approxi-

mately three billion nucleotides. Now, says Crandall, ìWe can

sequence a human genome for $1,000, and we can generate

more than 320 genomes per week!î

As life scientists explore more ways to deal with big dataís

volume, velocity, and variability, they are starting to develop

new approaches to analyzing information.

Ever-Expanding Volume

When it comes to collecting large volumes of information about

human biology, the pharmaceutical industry started battling

large data sets decades ago. As Jason Johnson, associate vice

� �)���*�� *)�����*��� �+�)*+*Merck Research Labs in

Boston, Massachusetts says, ìMerck has for many years had

clinical trials with thousands of patients, and the ability to query

�����)*��*���������*�+��* ��� �)�*+��*���*��*�+��*���*

generation genomic sequencing that can create a terabyte of

data per sample.î

To deal with so much data, even large pharmaceutical com-

�+��)*����*�����*�� *��+�����*� ��*���� )������+�*��+����*

������� +��)*+*Roche in Basel, Switzerland, says, ìA cen-

turyís worth of Roche R&D data were more than doubled in

�� !�� �*�*+*)������+ ���)�+������� ���*�*)�"���������-

� ��)*����+��� ���������)�#*���� )*+��*�)*�����+���)��+�*

���� ��*�� �*�+���*� ��*��)�*�++*)�)*+��*��� )*��������*

years ago. So they are collaborating with PointCross in Foster

$��*$+��� �+�*�*� �+�*+*�++*��+�� �*�+*+����)*%�����*

searching of data from the past 25 years of Roche studies,

including those outsourced to contract research organizations.

Those data, along with information about thousands of com-

pounds, will be mined to use the existing knowledge to develop

new drugs.

To generate large volumes of data, though, a biologist does

not need the infrastructure of a large pharmaceutical company.

�� *��+�����*���)�� *��*)�����+��)*��*��*&��*'� )��+�*

Genome Machine (PGM) System from Life Technologies in

Carlsbad, California (now a part of �������� �����������).

This next generation device can sequence up to two gigabases

in less than eight hours, and this is marketed as a ìpersonal

genome machineî that can go on a scientistís benchtop. Life

Technologiesí larger Ion Proton machine pumps out up to 10

gigabases in four hours or less.

In general, for academic and industrial life scientists, next

generation sequencing supplies a bonanza and a bottleneck.

As Crandall explains, ìWe cannot effectively study this volume

of genomes until our computational software scales up to these

big data needs.î So his team is working with W. Evan John-

son, an assistant professor of medicine at Boston University

School of Medicine, to develop software, PathoScope, that

can handle the data from todayís next generation sequencing

(NGS) platforms, which turn information on gigabases of DNA

into gigabytes of computer dataóthe exact ratio tends to be

about linear, depending on the NGS platform being used. This

software compares DNA samples to reference genomes in an

effort to identify a pathogen. Crandall says, ìOur data sets can

Big Biological Impacts from Big Data

Digital Lab ManagementóJuly 25 MetabolomicsóSeptember 19 GenomicsóOctober 3

PH

OT

O:

MA

KS

IM K

AB

AK

OU

/SH

UT

TE

RS

TO

CK

.CO

M

In the life sciences, data can come in many forms, including

information about genomic sequences, molecular pathways,

and different populations of people. Those data create a

potential bonanza, if scientists can overcome one stumbling

block: how to handle the complexity of information. Tools

and techniques for analyzing big data promise to mold mas-

sive mounds of information into a better understanding of

the basic biological mechanisms and how the results can be

applied in, for example, health care. By Mike May

Upcoming Features

Page 10: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the

1299SCIENCE sciencemag.org/products

LIFE SCIENCE TECHNOLOGIES

BIG DATA

Produced by the Science/AAAS Custom Publishing Office

CDECF��������������D���� C-

��C���D��D�� C���������������

����C������ C�C��������������

���D��� �������D����� ���

�� C����������D��D�C�����D�-

��CC������ ���������� ��

���D����CDEC�D�����������

��D��� �� ������!��C� ��

���"�������C��DC�����D���D-

������D��CEC���C���DEC���

����C��������# C����� ��C���

�� C��

������ ���C�D�C��C���

��������������������C�������

�E�C�$ ��������%��������

���&D�C�D��'��D��DCC���-

D����C�D�������CC���������

���D���������(������D��D���

)��� ���(����������D��

Rutgers University ���*�C�D�-

D�DE��+���&�C�E������D���C��

��$ ��� C�D����������������� ��

����D�����C�$ ���������������-

���C��$ ��C��������� �D����D��

C�D�����C�����D����������D�D�D��������DE�������������C�C������

�����������C��D�C�����������������C�D�D�E,�������C���D�C���D��

�������C�C�� C����D����� C��� �����-��������� �D����D������-

�������C��� ���DC�'��D�CDEC����D���� �C�D���CC ����������D�����

���������E�� ���C�������������.������C�� ����C���D��D���DCE�

���D������E��������D���� ���C��E������������������ ��E��������

����E����D���������C����D���D����D��D��D������� ������-

� ��CD��.�����������.�����E����D���CDEC�'��D���$ ��C�������

D�������C����������/C���������������

Versions of Variability

��������v���D�D�����E����D��C�D�������D�����������������C�C��%C�

�� ��D�CDEC���0��D������������������������������������C�

������������D�DC���������C��������������D�D�C��C��

��������������D�������E��D������ ��C�D��D���E������C� ����C��

D������E����������������D�D����C����.��.������D�C��1��ACD/

Labs,���D�$ D���������������)D�D�D���������������� �����

CEC���C���D�������D���D������D��������D�D��E��C���������-

��������������D�D��%C�2ED��1DCD������������������D��C�D���E�D��

%)�34D�C��� ��D��C���0��C �����������D��"5��.������D�C�

�����D�� C���C� ����C���6��D��C�����C����C� C�������D�D������

����������������� �1���� C��D�D�DC����������D������D���

D�D��D������� �����C����-�������C����D����D���CC������ ���

��������DC������DC���D�������D��D��E������D���C�CEC���C��

������E/C������D�D�D�C������ �����������C�����D�D�����E��

1������C�C�D��������������� ������7��D�E������ D������

D�D�E,����D����������D�E��D��C���CC ����������C����

�����D�����D�� ��D���CC ��CD����/C��D��- ���C ���DC������

C�,���C�D��������C�D��C���D�����E�D�C����D�������������C�

����D����D�����������C�������$ ���D�����D����������D�

�D���E����C� ���C��C ���DC����C����C���������

���8�����D�E��C�����D�D����CD��������� ����C����CD����C�

���������C��D��D�D�EC�C�����D�����"��/C�������D�E��C����

�D�D����CD������

1 ����D������ ��C�����D�D��D������C����D��E� C�� �������D����

�D����������D�D�� ���D��C������C�C�� C���D��������D��� ���

�����D�D�����E�D�������������������C������������� �������C��

�9� ��D�/���D��D�E��DC��D��������� C���F�EFC� �E���F���EF"��

��������� ��E� ��D������� ������������D�����CC��C��E�C� �E-

����CDE�5���������CDEC�)�DC��� ��D������CC������D�C�D����D��

���������D������University of Oxford, :������;��������4D��-

C�D���C� ���C����������D���������������� ����C������C�DC���

�������D�� ���� ��������D�C �C�������D�����C��������������-

��� D�C�D�������E������������D��D��� �D���C����

������ ���C�D�C��� ��������C���D�����������D��������-

�������D�D������D�����D����7������C�����C� C�D�� ��������� ��

�������������� ���C�D���������������������C����D�����D��

E� ��D�����D�� �������CDEC�7�����<�D�������CC�����C�D��C���D��

�������C�D������Wellcome Trust Centre for Human Genetics

���� �����:������;������������ D�������������������D�����

���������D������D��C���������D��C����D�C����.����������

��C�DC��������D������ ���������������D��D��� �D���������D�����

%C���<�D��� ��D��C���7������C��D�������E� ����D�����D���DC-

C���D���������D���C�DC���C������������D����DC�D�=���D�� ���>�

�D�����������C�D�����D������ �����D������C�D��D��� �D��������

�D������ ����D���D�������D���������D�����������C�DC��

��D���E����C�������������<�D��D�����C������D� �C�D����D�-

��������4��;D�1�����)��������6�D����?����D�����D�����C����E�

D��� ����:����C��E���������DC��D ���������D�� ��������� -

����@D�� ��ABB��������@����)����C���������D���4��;D-C������

��C���������������� ���D������D�D���C��� �����������C�� ����E�

��������������������D����CDEC���<�D�������������������

�������������D�D�E���D���D�D�����CC����D����������C��������

��C��� ����C������D���D�����C���������������E�� ���DC���D�����

$ �C����C�D�� �������������D���D�D�E,���������D�D�C��C��

Seeking High Velocity

���C������v���������E��������C�����C������������CC����D���

D�D�E,���������D�D��1������C�C����������-C���������CC�C����

D�D�E,���������������� ��C�����D�D�

?�������DC���D�D�E,��������-��D�����D�D���D����D�������-

�������D������D��E�����C��D�D�EC�C���D����C��D�����C�����-

� ������E������D����C�����C�D���C���CDECF%�D��D��������C������

��FBioDatomics ��������C�D���DE�D�������E/�����������.� ���

��� C����������$ �������������D����D��C ������D������E/���

D�C���������E�C�������� �� ��������!��C���?���D�������CDEC�����

�� ����D����DEC�������C����� ��D� ���D��D����+%�D�D�EC�C��

1������D�����C�������������C������C����D���������������C�

������D����������C����D�D�E,�������������D�D��?�������D��C�

���C������C����������C����D���D��D�������D���������DC������

C���D�������D��� � ��D�E���C��������� ���

����� �C����D����� ����� C�������������C�C�C�����D-

�����C���D���������C������-����������D����������DC�������9� �

�����D����DC���� �����C���CDECF�D ��������������������������-

�E���.���D�F����D�����C��9���������D�� ������D�E�����C����

����CC��D�D�������DC�����1�D�D�����E��C���������D��E� �����������

PH

OT

O:

QU

KA

/SH

UTT

ER

ST

OC

K.C

OM

ìOur data sets can be 20

gi gabytes of data per

sample for hundreds of

samples with downstream

analyses generat ing

100ís of gigabytes of

data per sample.î

continued>

Page 11: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the

1300 sciencemag.org/products SCIENCE

LIFE SCIENCE TECHNOLOGIES

BIG DATA

Produced by the Science/AAAS Custom Publishing Office

Complexity from

Combinations

To the three vís of big data,

Stephen Cleaver, execu-

tive director of informatics

systems at the Novartis

Institutes for BioMedi-

cal Research (NIBR) in

Cambridge, Massachusetts

adds complexity. He says

that scientists in the phar-

maceutical industry ana-

lyze the data by ìpatients

individually and then as a

group, and then we inte-

grate everything we have.î

That gets complex.

In health care, the com-

plexity of big data analysis

also arises from combining

different types of informa-

tion, such as data from

genomics, proteomics,

cellular signaling, clinical research, and even environmental

studies. The results could reveal entirely new approaches to

treating diseases. But Iya Khalil, cofounder of GNS Healthcare

in Cambridge, Massachusetts, asks: ìHow do you make sense

of those data and get insights from those data that will advance

our understanding of the disease mechanism?î For Khalil and

her teammates, the answer comes from machine learning,

mathematics, computational algorithms, and supercomputersó

all combined to explore the underlying pathways of disease and

to follow a patientís likely response to a particular treatment.

At GNS Healthcare, such big-data analysis depends on a

computational platform called REFS, which stands for reverse

engineering and forward simulation. In short, the software ana-

lyzes data to construct possible molecular networks underlying

&'()����'�'��(�&(����&��('���'��(�')&��&��'����'��'�(�('��&�'

�� ��&����'���(����&������'��)&��'&')&�����&'���)����'�����'

have upon the pathwayóthe forward aspect of the process.

In addition to health care, REFS can be applied to basic

biology. For example, Khalil and her colleagues have used this

technology to make a molecular model of part of the cell repli-

cation cycle.

For Khalil and other scientists, the key is using big data in

ways that move science forward. At NIBR, for instance, Cleaver

and his colleagues want to make sure that the data is informa-

����'�'(�'&��' ����(��'����('��&�'��'��'&�&����'�&�&�������'

������(�'���'��'��(�'(����(�'���'����'(�������'�'��)����(�(��'��'

says. That way, todayís big data will change tomorrowís biology

and medicine.

track the characteristic

changes cells undergo

during development,

measure the impact that

environmental factors have

on an organism, or that

quantify the cellular effects

a medication may have on

()����'�'��((��(�

Structured data, such

as tables of numbers, do

not reveal everything that

is known about a medica-

tion or biological process.

Much of what we know

about living organisms ex-

ists in unstructured formats,

like journal article text. As

Johnson of Merck says,

ìThere are thousands of

ways to describe biological

processes,î and it is dif-

�'����'��'���&��'�&�&' ��'

the literature.

At IBMís Almaden Research Center in San Jose, California,

analytics expert and research staff member Ying Chen and her

colleagues have worked for years on creating technologies for

mining text, which they now use for their ìaccelerated drug

discovery solution.î Their platform aggregates patents, scien-

���'�'����&����'�&(��'�����(��'&��'�������'���������'�(���'&('

how chemicals and molecules interact), more than 16 million

unique chemical structures, and information about nearly 7,000

diseases. Using this system, researchers can search for com-

)����('��&�'�����'��'�(� ��' �'��&����'()����'�'��(�&(�(�

Other companies also hope to mine existing resources to

learn more about the biology of diseases and how to treat

them. NuMedii, a big-data company in Silicon Valley, and

����(��' ����(�'&')����'� '�����������'(�������'�'�� ��&�

����'��'!��'"���'�&�'��&���'�)'��'�'��'���'�(�(' �'���(����'

drugs, known as drug repurposing. ìUsing genomic databases,

integrated knowledge sources, and bioinformatic approaches,

we can quickly discover novel uses for drugs,î says Craig

#����'!�$�����('���� '(�������'�'� �'���'�#�'����'���&��'���'

safety data for the drugs in their original use to get to clinical

trials faster and cheaper.î NuMedii is contributing databases

and analytics to the project, while Thomas Reuters is supplying

in-depth knowledge on diseases and drugs.

One such project, Webb says, has researchers compiling

gene expression data from more than 2,500 ovarian tumor

samples and using several computer algorithms to predict

whether any existing drugs could potentially treat ovarian

�&���'��&���'�'��&�'()����'�'�������&'(����)�(�'�%��'�&�&'

allows us to cast a wide net initially to identify leads, while ëbig

knowledgeí allows us to quickly select viable compounds to

test,î Webb says. DOI: 10.1126/science.opms.p1400086

ACD/Labswww.acdlabs.com

BioDatomicswww.biodatomics.com

Boston University School of Medicinewww.bumc.bu.edu/busm

���������

�������'����(����

George Washington Universitywww.gwu.edu

GNS Healthcarewww.gnshealthcare.com

IBMwww.ibm.com

Life Technologieswww.lifetechnologies.com

Merckwww.merck.com

Novartis Institutes for BioMedical Researchwww.nibr.com

NuMediiwww.numedii.com

Rochewww.roche.com/index.htm

Rutgers, The State University of New Jerseywww.rutgers.edu

������������ ���������

����������'(������

University of Oxfordwww.ox.ac.uk

Wellcome Trust Centre for Human Geneticswww.well.ox.ac.uk

Mike May is a publishing consultant for science and technology.

Featured Participants

Page 12: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the

1301SCIENCE sciencemag.org/products

LIFE SCIENCE TECHNOLOGIES

NEW PRODUCTS: BIG DATA

Produced by the Science/AAAS Custom Publishing Office

Digital Gene Expression AssayThe nCounter PanCancer Pathways

Panel is a highly multiplexed, digital gene

expression assay that offers a unique way

to investigate cancer biology across all

major cancer pathways. From a single

tube, the PanCancer Pathways Panel

simultaneously analyzes all of the key

cancer pathways: PI3K, STAT, MAPK,

� !"��������������������� ����������

������������� �������������������-

�������������������������������������� �

Damage Control. The 770 genes included

in the PanCancer Pathways Panel were

selected using a biology-guided, data-

driven methodology that provides high

��������������������������������������

each cancer pathway was captured.

Each of the canonical cancer pathways

was mapped to publicly available data

sources such as Kyoto Encyclopedia of

Genes and Genomes (KEGG), Reactome,

and the Gene Ontology (GO) databases.

Then, leveraging data generated through

The Cancer Genome Atlas (TCGA) and

the collective work of decades of cancer

research, each pathway gene and driver

gene was scored and ranked based on its

biological relevance to cancer.

NanoString Technologies

For info: 888-358-6266

www.nanostring.com/pancancer

Compound Screening SoftwareThe new version of the StarDrop software

platform introduces MPO Explorer, which

provides innovative new methods to

guide strategic decisions in research pro-

grams by helping to identify the key prop-

erties and selection criteria with which

to select compounds with a high chance

of success. MPO Explorer introduces

unique methods that guide the develop-

ment and validation of multi-parameter

���������� ������� ������������������������������������������������

�������� �������������� ���������� ������������������������-

bilistic Scoring approach for multi-parameter optimization (MPO), to

effectively target novel compounds with a high chance of success.

The most important property criteria are also highlighted, focusing

experimental resources to generate the key data with which to iden-

tify successful compounds. To promote objective decision-making,

����������� ��� ������������������������������������������������

��� ����������������� ������������������ ��������������������

pursue.

Optibrium

For info: +44-(0)-1223-815900

www.optibrium.com

Electronically submit your new product description or product literature information! Go to www.sciencemag.org/products/newproducts.dtl for more information.

Spectral Analysis SoftwareKnowItAll ATR/IR ID Expert and Raman ID

Expert are new technologies that provide

the fastest, most accurate answers pos-

sible to scientists identifying unknown infra-

red and Raman spectra. The spectral intelli-

gence built into KnowItAll ATR/IR ID Expert

���� ���� ��������������������������������

reference collection provides the highest

level of expertise to any scientist, whether

a novice or power user. Scientists often

employ multiple software tools to identify a

spectrum depending on its chemical com-

position and the availability of reference

spectra, and even the most experienced

���������������� � ����������������� ���

ATR/IR ID Expert and Raman ID Expert, the

user simply opens an unknown spectrum

and the software automatically performs

single and multiple component searches

as well as functional group analyses simul-

taneously and summarizes the results on a

single screen. If there are problems with the

�����������������������������������������

spectral intelligence to identify these issues

����������������������������

Bio-Rad

For info: 888-524-6723

www.knowitall.com

High-Content Screening Platform A new high-content screening software

platform enables cancer researchers to

uncover more about basic and advanced

cellular function to accelerate cell-based

������������������������������� ��

Studio 2.0 is a high-content quantitative

imaging and analysis software platform

for a range of cancer research applica-

tions, including angiogenesis and migra-

tion/invasion, as well as the development

of three-dimensional models of cancer

stem cells and spheroid tumors. The new

����������������� ������������������������������������������

high-content analysis platforms, are increasingly being used in can-

cer biology as they are well suited for large-scale, high throughput

biology, including complex morphological analyses of cells, cell

structure, and aggregations of cells in colonies, yet simple enough

to be applied to everyday assays such as viability and prolifera-

tion. The challenges posed by complex cancer applications and

cell models demand new types of quantitative analysis techniques,

and the new software provides innovative assay techniques and

functionality.

������������� ������ �

For info: 866-984-3766

���������� �����������"��������

DNA Copy Number Variation ArrayThe range of research-validated CytoSure

Molecular Arrays has been expanded to in-

�� ������������������������������#��$%�

underlying a variety of genetic disorders.

'�������� ��������������������������������

sequencing, providing a particularly powerful

tool for investigating the variety of aberra-

tions underlying genetic disorders. Compara-

������������������&���������� �#��(�%�

������������ �������������$�������������

the 60-mer oligonucleotide probes utilized

���!('� ���(�������������������� ����

����������� ����������$�������������������-

native platforms. The expanded CytoSure

Molecular Array portfolio now enables detec-

���������$����� �� ������������������� �

genetic disorders, including cardiovascular,

inherited eye, intellectual disability, and neu-

romuscular disorders, as well as a range of

inherited cancers. In addition, genes covering

each disorder can be combined to create

bespoke custom arrays, or further custom-

ized by the addition of novel content to suit

each individual research project. All CytoSure

��������������� ����� �������������!('� �

class-leading CytoSure Interpret Software.

Oxford Gene Technology

For info: +44-(0)-1865-856800

www.ogt.com/cytosure

Newly offered instrumentation, apparatus, and laboratory materials of interest to researchers in all disciplines in academic, industrial, and governmental organizations

are featured in this space. Emphasis is given to purpose, chief characteristics, and availability of products and materials. Endorsement by Science or AAAS of any

products or materials mentioned is not implied. Additional information may be obtained from the manufacturer or supplier.

Page 13: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the

Integrating Science, Engineering, and Medicine

NEUROLOGY

ATheoretically Based Index of ConsciousnessIndependent of Sensory Processing and BehaviorA. G. Casali et al. (M. Massimini), Sci. Transl. Med. 5 198ra105 (2013)

IMMUNOLOGY

TGFβReceptorMutations Impose a StrongPredisposition for Human Allergic DiseaseP.A. Frischmeyer-Guerrerio et al. (H. Dietz), Sci. Transl. Med. 5 195ra94(2013)

BIOENGINEERING

AHumanDiseaseModel of Drug Toxicity-InducedPulmonary Edema in a Lung-on-a-ChipMicrodeviceD. Huh et al. (D. Ingber), Sci. Transl. Med. 5 159ra147 (2012)

CANCER

Genome-WideMutational Signatures of AristolochicAcid and its Application as a Screening ToolS.L. Poon et al. (B. T. Teh), Sci. Transl. Med. 5 197ra101 (2013)

TISSUE ENGINEERING

Human Cartilage Repair with a PhotoreactiveAdhesive-Hydrogel CompositeB. Sharma et al. (J.J. Elisseeff ), Sci. Transl. Med. 5 167 ra6 (2013)

Join the ranks of high-profile paperspublished in Science Translational Medicine:

Publishing results that harness thebasic sciences to advance humanhealth in all areas of medicine

[email protected]

Chief Scientif ic Advisors

Elazer Edelman, M.D., Ph.D.Massachusetts Institute of Technology

Garret FitzGerald, M.D.University of Pennsylvania

Editor

Katrina L. Kelner, Ph.D.

AAAS, Washington, DC

Submit your researchScienceTranslationalMedicine.org

Recommend to your libraryScienceOnline.org/recommend

Page 14: BD Horizon Brilliant - Science · Produced by the Science/AAAS Custom Publishing Office ì îís hottest concepts, but it can be misleading. The name itself suggests ís just the

Recommended